幹性（非血管增生型），沒有什麽有效治療手段。
濕性（血管增生型），可以考慮激光治療，或最近研發的一些免疫藥物。
具體請谘詢醫生。
A randomized control trial found that bevacizumab and ranibizumab had similar efficacy, and reported no significant increase in adverse events with bevacizumab.[53] A 2014 Cochrane review found that the systemic safety of bevacizumab and ranibizumab are similar when used to treat neovascular AMD, except for gastrointestinal disorders.[54] Bevacizumab however is not FDA approved for treatment of macular degeneration. A controversy in the UK involved the off-label use of cheaper bevacizumab over the approved, but expensive, ranibizumab.
來源：Wiki
